Approved Use: TAVNEOS® is a prescription medicine that is used with other medicines (such as glucocorticoids) to treat adults with severe
Read moreApproved Use: TAVNEOS® is a prescription medicine that is used with other medicines (such as glucocorticoids) to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA], formerly known as Wegener’s granulomatosis, and microscopic polyangiitis [MPA]). It is not known if TAVNEOS is safe and effective in children under the age of 18.
Read lessThe link you have selected will take you away from the TAVNEOS® (avacopan) website to one that is not owned or controlled by ChemoCentryx. ChemoCentryx accepts no responsibility for the content of linked sites.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click “OK” if you are a healthcare professional.
Based on your location, you are being redirected to the website of our licensee Vifor Fresenius Medical Care Renal Pharma Ltd. CCXI does not have responsibility for, or control of, the contents, availability, operation, or performance of the website.
Eligible commercially insured patients may pay as little as $0 for a month’s supply of TAVNEOS® with the TAVNEOS® Connect Copay Program*,†
TAVNEOS® Connect services are available for adult patients whose diagnosis is aligned with the FDA-approved indication for TAVNEOS®. Additional eligibility criteria and other terms and conditions apply.
Terms, conditions, and program maximums apply. Other restrictions may apply. This program is not open to patients receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, or for cash patients. This is not insurance or a guarantee of payment. No cash value. Void were prohibited by law.
87% of insured patients, regardless of formulary coverage, were approved for TAVNEOS®
Time to fill is 7 days or less for most patients, regardless of insurance approval
TAVNEOS® Connect services are available for adult patients whose diagnosis is aligned with the FDA-approved indication for TAVNEOS®. Additional eligibility criteria and other terms and conditions apply.
Terms, conditions, and program maximums apply. Other restrictions may apply. This program is not open to patients receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, or for cash patients. This is not insurance or a guarantee of payment. No cash value. Void were prohibited by law.
Start by calling the TAVNEOS® Connect Team to understand your options. For eligible patients who are uninsured or are unable to afford their medication, the TAVNEOS® Patient Assistance Program may help provide access to TAVNEOS®. If you are unable to access TAVNEOS® after completing the prescription process, you may complete a Patient Assistance Program application and undergo screening by the TAVNEOS® Connect Team. Patients must meet eligibility criteria related to age, diagnosis, income, residency, and insurance status.
For any questions, call the TAVNEOS® Connect Team at 1-833-TAVNEOS
(1-833-828-6367)
and choose option 2, Monday through Friday from 8 AM to 8 PM ET
TAVNEOS can cause serious side effects, including:
Your healthcare provider will do blood tests to check how well your liver is working before starting and during your treatment with TAVNEOS.
The most common side effects of TAVNEOS include:
TAVNEOS is a prescription medicine that is used with other medicines (such as glucocorticoids) to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA], formerly known as Wegener’s granulomatosis, and microscopic polyangiitis [MPA]).
These are not all the possible side effects of TAVNEOS. Call your doctor for medical advice about side effects. Please see the Full Prescribing Information and Medication Guide for further details.
TAVNEOS is available as a 10 mg capsule.
You are encouraged to report negative side effects to Amgen at 1-833-828-6367 or to the FDA by
visiting www.fda.gov/medwatch or calling 1-800-332-1088.
IMPORTANT SAFETY INFORMATION What is the most important information I should know about TAVNEOS? TAVNEOS can cause serious side effects, including: Liver problems. People taking TAVNEOS may have serious liver problems. Call your healthcare provider right away if you have unexplained symptoms such as: